Q-omics provides the consensus-scored PDE11A profile across patient tissues and cancer cell-line models. PDE11A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PDE11A is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, PDE11A RNA expression shows 16,082 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, THCA, and TGCT as cancer lineages where PDE11A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE11A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE11A survival associations across molecular data types. PDE11A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (11) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE11A RNA expression–survival associations across cancer types. High PDE11A expression shows unfavorable associations in LUAD, BLCA, THCA and SKCM, but favorable associations in KIRC and SCLC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PDE11A RNA expression.
This table summarizes PDE11A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PDE11A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE11A shows lower tumor expression in THCA, BRCA and READ and higher tumor expression in KIRC, KICH and LUAD. The THCA box plot shows higher PDE11A RNA expression in normal versus tumor tissue (log2 FC = −1.301, t-test p < 0.001).
This table shows molecular features associated with PDE11A in patient tissues and cancer cell lines. In patient samples, PDE11A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PDE11A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
